ACM
CNTX icon

AIGH Capital Management’s Context Therapeutics CNTX Stock Holding History

AIGH Capital Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,143,745
Closed -$745K – 54
2022
Q4 		$745K Sell
1,143,745
-148,026
-11% -$159K 0.25% 42
2022
Q3 		$1.43M Buy
1,291,771
+100,000
+8% +$180K 0.45% 33
2022
Q2 		$1.19M Buy
+1,191,771
New +$2.23M 0.31% 33
2022
Q1 		– Sell
-762,721
Closed -$2.03M – 45
2021
Q4 		$2.03M Buy
+762,721
New +$3.8M 0.62% 35

Other funds holding CNTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIGH Capital Management's CNTX Position: Q1 2023 in Review

AIGH Capital Management sold out of Context Therapeutics (CNTX) in Q1 2023, closing a stake of 1,143,745 shares — an estimated $745K sold.

AIGH Capital Management first reported a position in CNTX in Q4 2021 and held it in 4 quarters. The position peaked at $2.03M in Q4 2021. 22 funds tracked by Wall St. Rank hold CNTX as of Q1 2023.

  • AIGH Capital Management reported no remaining Context Therapeutics position as of Q1 2023 after selling out during the quarter.
  • AIGH Capital Management sold 1,143,745 Context Therapeutics shares in Q1 2023, an estimated $745K.
  • AIGH Capital Management first reported a position in Context Therapeutics in Q4 2021 and held it in 4 quarters.
  • AIGH Capital Management's Context Therapeutics position peaked at $2.03M in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2023.

Based on AIGH Capital Management's 13F filing for Q1 2023, filed 15 May 2023.